Agenda | Management Board
59th Meeting

Date: 27–28 June 2019
Venue: Lisbon
Chair: Laura d’Arrigo

Thursday, 27 June 2019
14.30–17.00

1. Adoption of the agenda
   1.1. Annotated agenda

2. Activity reports:
   2.1. Report on the activities of the Chair
   2.2. Report from the Budget Committee
   2.3. Report on the external activities of the Director

3. Presentations by the EU Presidencies:
   3.1. Presentation on the conclusions of the Romanian Presidency
   3.2. Presentation on the programme of the Finnish Presidency

4. Budget and financial issues:
   4.1. New Financial Regulation applicable to the EMCDDA (for adoption)
   4.2. EMCDDA 2018 final accounts: opinion of the Management Board (for adoption)
   4.3. Amending budget no. 1 to the EMCDDA 2019 budget (for adoption)
   4.4. Information on procurements for non-administrative activities of a value greater than EUR 60 000 to implement the 2019 work programme (for information)
   4.5. Measures to rationalise expenditure on budget title ‘Statutory meetings’ (for decision)
   4.6. EMCDDA’s budget for 2020: oral report on the state of play of the budget procedure by the European Commission (for information)

5. International cooperation:
   - Candidate and potential candidate countries:
     5.1. Working arrangements between the EMCDDA and Western Balkan countries (Kosovo*, Serbia) (for decision)
   - European Neighbourhood Countries:
     5.3. Working arrangement between the EMCDDA and Ukraine (for decision)
     5.4. Working arrangement between the EMCDDA and Algeria (for decision)
     5.5. ‘EU4 Monitoring Drugs’ project (for information)

17.00 Reception with the EMCDDA staff (Cais do Sodré)

---

*This designation is without prejudice to positions on status, and is in line with UNSCR 1244 and the ICJ Opinion on the Kosovo declaration of independence. This applies to all mentions of Kosovo in this document.
6. Drug situation in Europe
   6.1. Main trends of the drug situation in Europe as presented in the 2019 European Drug Report
   6.2. Launch and uptake of the 2019 European Drug Report

7. Performance and internal controls:
   7.2. End-term monitoring report of the EMCDDA 2016–18 Strategy and Work Programme (for information)
   7.3. State of implementation of the recommendations issued by the Internal Audit Service (IAS) (for information)
   7.4. EMCDDA Action Plan further to the 2018 IAS Audit on ‘Publications Management’ (for endorsement)

8. Data protection and prevention and management of conflicts of interest:
   8.1. EMCDDA Implementing Rules for new Regulation (EU) 2018/1725 on Data Protection (for adoption)
   8.2. Periodic assessment of the implementation of the EMCDDA Policy for the prevention and management of conflicts of interest for Management Board members, substitutes and observers (for decision)

9. Any other business
   9.1. Planning of meetings for 2020 (for endorsement)